Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rema Raman

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
JAMA Neurology|July 23, 2019
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical TrialChristopher H van Dyck, Haakon B Nygaard, Kewei Chen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
Pediatrics|May 10, 2020
Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled TrialCynthia Sharpe, Gail E Reiner, Suzanne L Davis, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer's DiseaseMabel Seto, Hannah M Klinger, Michelle Clifton, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2025
Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTERKathryn V Papp, Sarah Tomaszewski Farias, Marjorie Howard, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 10, 2024
The AUstralian multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention study (AU-ARROW): A study protocol for a single-blind, multi-site, randomized controlled trialSamantha L Gardener, Stephanie J Fuller, Sharon L Naismith, et al.
Imaging Neuroscience (Cambridge, Mass.)|August 13, 2025
Establishing tau-PET cut-points for cognitive diagnosis with <sup>18</sup> F-PI-2620 in a multi-ethnoracial cohortVictoria R Tennant, Koral V Wheeler, Noelle N Lee, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Basic Science and PathogenesisMabel Seto, Hannah M Klinger, Vaibhav A Janve, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 22, 2026
Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adultsHannah M Klinger, Mabel Seto, Vaibhav A Janve, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
JAMA Neurology|July 23, 2019
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical TrialChristopher H van Dyck, Haakon B Nygaard, Kewei Chen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
Pediatrics|May 10, 2020
Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled TrialCynthia Sharpe, Gail E Reiner, Suzanne L Davis, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer's DiseaseMabel Seto, Hannah M Klinger, Michelle Clifton, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2025
Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTERKathryn V Papp, Sarah Tomaszewski Farias, Marjorie Howard, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 10, 2024
The AUstralian multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention study (AU-ARROW): A study protocol for a single-blind, multi-site, randomized controlled trialSamantha L Gardener, Stephanie J Fuller, Sharon L Naismith, et al.
Imaging Neuroscience (Cambridge, Mass.)|August 13, 2025
Establishing tau-PET cut-points for cognitive diagnosis with <sup>18</sup> F-PI-2620 in a multi-ethnoracial cohortVictoria R Tennant, Koral V Wheeler, Noelle N Lee, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Basic Science and PathogenesisMabel Seto, Hannah M Klinger, Vaibhav A Janve, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 22, 2026
Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adultsHannah M Klinger, Mabel Seto, Vaibhav A Janve, et al.
Pageof 20